Proteomics player SomaLogic pulls in $200M in financing round

Money
Proteomics player SomaLogic pulled in $200M in a financing round led by iCarbonX.

SomaLogic, a Colorado-based developer of a technology used for analyzing proteins for personalized medicine and proteomics, pulled in $200 million in a financing round led by iCarbonX. The money will be used to speed up the company’s target of becoming the global leader in precision digital health insights.

Other investors in the round included Nan Fung Life Sciences and Madryn Asset Management. Additional details of the funding weren’t disclosed.

SomaLogic’s SOMAscan is capable of measuring thousands of human proteins rather than genes. Currently, the technology has been used to successfully analyze more than 150,000 samples covering 50 diseases or conditions. The company says it plans for an additional 1 million samples by the end of 2020.

Whitepaper

Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“We believe SomaLogic’s proteomics technology provides the basis for unique and differentiated insights into human health and disease, with broad implications for diagnosis and treatment,” Avinash Amin, managing partner at Madryn Asset Management, said in a statement.

The ability to understand how bodily proteins change over time is being recognized in the health industry as a new avenue to personalize the treatment and management of diseases. Proteins, unlike genes, respond to changes in the body and the environment, providing better health information in real-time.

Read more on

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

Five years after Congress passed a law to reduce unnecessary MRIs and CT scans, federal officials have yet to implement it.